
A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters
In the notoriously flighty biotech industry, longtime partnerships aren’t necessarily the norm. But a pair of oncology vets with a history of collaboration apparently likes working together just fine — and now they’re kickstarting an upstart firm on the hunt against solid tumors.
Rondo Therapeutics launched Wednesday with a $67 million Series A and backing from J&J, among others, to build out its platform of next-gen T cell engagers and bispecific antibodies targeting solid tumors, the new biotech said in a release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.